Research programme: type 1 diabetes therapeutics - MultiCell Technologies
Alternative Names: MCT 275Latest Information Update: 04 Nov 2017
At a glance
- Originator MultiCell Technologies Inc
- Class
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Type 1 diabetes mellitus
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (Parenteral, Injection)
- 24 May 2006 Preclinical trials in Type-1-diabetes-mellitus in USA (unspecified route)